Based on the measurements of operating efficiency obtained from AtriCure's historical financial statements, AtriCure may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At present, AtriCure's Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Liabilities And Stockholders Equity is expected to grow to about 639.8 M, whereas Retained Earnings are projected to grow to (381.7 M). Key indicators impacting AtriCure's financial strength include:
Investors should never underestimate AtriCure's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor AtriCure's cash flow, debt, and profitability to make informed and accurate decisions about investing in AtriCure.
Net Income
(42.46 Million)
AtriCure
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Average Inventory
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Capital Expenditures
Total Cash From Financing Activities
End Period Cash Flow
Change To Liabilities
Change To Inventory
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Total Cash From Operating Activities
Net Income
Change To Account Receivables
Total Cashflows From Investing Activities
Stock Based Compensation
Other Cashflows From Investing Activities
Sale Purchase Of Stock
Investments
Change Receivables
Net Borrowings
Exchange Rate Changes
Dividends Paid
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Netincome
Change To Operating Activities
Total Assets
Total Stockholder Equity
Retained Earnings
Other Assets
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Other Stockholder Equity
Total Liab
Other Current Liab
Total Current Liabilities
Accounts Payable
Cash
Inventory
Other Current Assets
Common Stock
Property Plant Equipment
Property Plant And Equipment Net
Net Debt
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Net Receivables
Common Stock Total Equity
Non Current Liabilities Total
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Short Long Term Debt Total
Long Term Debt
Good Will
Short Term Investments
Short Term Debt
Intangible Assets
Other Liab
Current Deferred Revenue
Net Tangible Assets
Retained Earnings Total Equity
Long Term Debt Total
Capital Surpluse
Non Current Liabilities Other
Long Term Investments
Short Long Term Debt
Capital Lease Obligations
Net Invested Capital
Net Working Capital
Capital Stock
Interest Expense
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Tax Expense
Selling General Administrative
Research Development
Depreciation And Amortization
Income Before Tax
Total Other Income Expense Net
Net Income From Continuing Ops
Non Operating Income Net Other
Net Income Applicable To Common Shares
Tax Provision
Interest Income
Net Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past AtriCure Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of AtriCure's financial statements are interrelated, with each one affecting the others. For example, an increase in AtriCure's assets may result in an increase in income on the income statement.
Please note, the presentation of AtriCure's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AtriCure's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of AtriCure's management manipulating its earnings.
AtriCure Stock Summary
AtriCure competes with AngioDynamics, LeMaitre Vascular, CONMED, and Axogen. AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company was incorporated in 2000 and is headquartered in Mason, Ohio. Atricure operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 875 people.
Comparative valuation techniques use various fundamental indicators to help in determining AtriCure's current stock value. Our valuation model uses many indicators to compare AtriCure value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AtriCure competition to find correlations between indicators driving AtriCure's intrinsic value. More Info.
AtriCure is rated fourth in return on equity category among its peers. It is rated fifth in return on asset category among its peers . At present, AtriCure's Return On Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the AtriCure's earnings, one of the primary drivers of an investment's value.
AtriCure's Earnings Breakdown by Geography
AtriCure Systematic Risk
AtriCure's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. AtriCure volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on AtriCure correlated with the market. If Beta is less than 0 AtriCure generally moves in the opposite direction as compared to the market. If AtriCure Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one AtriCure is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of AtriCure is generally in the same direction as the market. If Beta > 1 AtriCure moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in AtriCure Stock are looking for potential investment opportunities by analyzing not only static indicators but also various AtriCure's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of AtriCure growth as a starting point in their analysis.
Price Earnings To Growth Ratio
(0.7)
At present, AtriCure's Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.
AtriCure March 18, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of AtriCure help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of AtriCure. We use our internally-developed statistical techniques to arrive at the intrinsic value of AtriCure based on widely used predictive technical indicators. In general, we focus on analyzing AtriCure Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build AtriCure's daily price indicators and compare them against related drivers.
When running AtriCure's price analysis, check to measure AtriCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AtriCure is operating at the current time. Most of AtriCure's value examination focuses on studying past and present price action to predict the probability of AtriCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AtriCure's price. Additionally, you may evaluate how the addition of AtriCure to your portfolios can decrease your overall portfolio volatility.
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance